MEDICALSAN acquired by COLOSSEUM DENTAL GROUP

Mehiläinen Group acquired 100% of Aleris Group from Triton Partners in a transformational pan-European healthcare transaction. The deal was structured via a definitive share purchase agreement that pooled institutional equity from Mehiläinen's financial sponsors, CVC Capital Partners and Hellman & Friedman, alongside tailored cross-border corporate debt facilities. While the exact financial terms of the purchase price remained undisclosed, the transaction successfully integrated Aleris into Mehiläinen’s international operations as a distinct, specialized care platform. Under the binding terms of the agreement, Aleris Group CEO Sofia Palmquist retains her operational leadership role to ensure regional business continuity alongside Mehiläinen Group CEO Janne-Olli Järvenpää. This acquisition immediately expands Mehiläinen’s Scandinavian footprint into Norway and Denmark while drastically scaling its existing Swedish Meliva brand, creating a combined healthcare powerhouse with 60,000 professionals across 1,500 locations positioned to deliver highly integrated, digitally powered outpatient care pathways across Europe.

The full realization of the investment by the Permira Funds via a 100% equity sale to Jardine Matheson constitutes a total platform exit executed in May 2026. This divestment concludes an active period of liquidity distributions for the sponsor following multiple high-profile exits across its global portfolio earlier in the year. The transaction marks the transition of the asset from an aggressive private equity build-up phase to a long-term institutional holding structure. Strategic value realization follows a comprehensive digital transformation that embedded machine learning tools into the core radiology workflow, expanding the company's geographical reach into international markets. Final completion of the acquisition remains subject to customary regulatory approvals and foreign investment clearances, with closing anticipated later in 2026.

Merieux Equity Partners acquired a significant minority stake in Health in Code, joining forces with Alantra and the management team. The transaction aims to provide the capital and industrial expertise needed to double the company's size, with a goal of reaching EUR100 million in revenue within five years. The strategic rationale focuses on aggressive international expansion into key European markets, enhancing the bioinformatics software suite, and pursuing selective M&A to consolidate the fragmented European genetics market.

Dentalcorp Holdings Ltd. has successfully completed a statutory plan of arrangement to be acquired by an acquisition vehicle affiliated with GTCR. Under the terms of the agreement, GTCR acquired all issued and outstanding subordinate and multiple voting shares for C$11.00 per share in cash. The transaction represents a premium of approximately 33% over the 20,day volume weighted average trading price prior to the initial announcement in September 2025. Following the completion of the deal, the company is expected to be de,listed from the Toronto Stock Exchange and will cease to be a reporting issuer in Canada. As part of the strategic structure, the founder and senior executive leadership, alongside certain partner dentists, rolled a significant portion of their existing shares into the post,closing capital structure. This rollover ensures leadership continuity and aligns the interests of the management team with the new private ownership. The acquisition provides the organization with enhanced flexibility as a private entity to invest in technology, patient care infrastructure, and professional development. The transaction was unanimously recommended by a Special Committee of independent directors and the Board of Directors, following a comprehensive negotiation process designed to crystallize value for shareholders while supporting the group's long,term expansion.

Point Vision acquired a controlling stake in Refract SAS, the parent company of Clinique de la Vision. This acquisition allows Point Vision to integrate a leading refractive surgery capability into its vast consultation network. The target retains its identity and organization, but a medical advisory committee will be established to harmonize governance. This build-up follows the roadmap set by Ares Management (majority owner since 2021) to expand the group's medical offering.

Terveystalo signed an agreement to acquire Hohde Group, comprising Hammas Hohde Oy and Loisto Laboratoriot Oy, in a transaction financed through debt committed by Terveystalo's existing partner banks. The acquisition is subject to approval by the Finnish Competition and Consumer Authority. The transaction directly supports Terveystalo's stated strategic objective of doubling its oral health business and becoming one of Finland's leading oral health companies, as communicated at its 2024 Capital Markets Day. Significant value creation is expected through growth and cost synergies, anticipated to materialise primarily within 36 months of closing. The transaction is expected to be earnings per share accretive from the first full year following completion.

CIR has signed a binding agreement to acquire the remaining 40.23% stake in KOS Group from F2i Healthcare (controlled by F2i Sgr and its co-investors), moving to 100% ownership. The strategic rationale for the transaction is to consolidate full industrial control over CIR's most strategic asset, enabling simplified governance and a more agile execution of KOS's expansion plans in Italy and Germany. By deploying its available cash reserves, CIR eliminates minority leakage and positions itself to capture the full upside of KOS’s performance recovery. The deal structure includes a potential earn-out based on future performance thresholds and an anti-embarrassment clause valid through mid-2028. This move marks the successful exit of the financial partner after a nine-year investment cycle and reinforces CIR’s long-term commitment to the healthcare infrastructure sector as its primary growth engine.

The Paris-based radiology group with approximately EUR80 million in revenue, backed since 2019 by UI Investissement, has just concluded a second LBO under the impetus of Metric Capital Partners, which would value it between EUR350 million and EUR400 million, according to our information, a little over a year after the abandonment of its takeover by Antin IP.

Groupe Resonance Imagerie, a french medical imaging group supported by Andera Partners for the past three years, is pursuing its geographical consolidation strategy by acquiring the Parisian company Cimep, which brings it 12 centers and nearly EUR20 million in additional revenue. The organization operates as a high-fidelity practitioner-led platform, focusing on the seamless integration of radiology expertise with advanced medical imaging technologies. Rather than focusing solely on basic diagnostics, the firm thrives on a philosophy of technical operational depth, managing a distributed network of centers that provide high-capacity scanning, MRI, and ultrasound services. Its value proposition centers on maintaining a strong medical project led by senior practitioners, ensuring high clinical standards for patients in the Val-de-Marne and Seine-Saint-Denis areas.

Bridgepoint acquired MyDentist from its long-term owners (likely Palamon Capital Partners and The Carlyle Group). Bridgepoint aims to accelerate the group's pivot from low-margin NHS contracts toward high-growth private treatments (implants, aesthetics, clear aligners). Leveraging its prior success with Oasis Dental Care, Bridgepoint plans to implement a rigorous operational efficiency program, utilizing digitalization and AI to optimize chair utilization and patient triage. Furthermore, MyDentist will serve as a consolidation platform, aggressively acquiring smaller independent practices to realize economies of scale in a fragmented market.